La bioventure RudaCure se asocia con Onhil y Onhil Pet para fármacos veterinarios

RudaCure Inc. (CEO Yongho Kim), a bio-venture company specializing in trastorno sensorial diseases, has firmó un comprehensive MOU for veterinario desarrollo de fármacos, producción, and sales with Onhil Co., Ltd. (CEOs Kim Do-hyung and Yoo Jeong-woo) and Onhil Pet Co., Ltd. (CEOs Ko Hyun-gyu and Ryu Tae-seong), empresas specializing in farmacéutico veterinario ensayo clínicos and distribución.

Under this acuerdo, the three empresas will initially co-develop tratamientos for animal de compañías, including ear inflammation tratamientos, ojo seco and daño corneal tratamientos, and dermatological formulacións.

RudaCure Inc., which holds desarrollo de fármacos know-how and patents, will be responsible for desarrollo de fármacos, while Onhil Co., Ltd. and Onhil Pet Co., Ltd. will handle veterinario ensayo clínicos, producción, and sales.

RudaCure Inc. already has licensing experience with tratamiento de la enfermedad de ojo secos and daño corneal tratamientos in 2021 and 2023, and actualmente está also developing a best-in-class powerful analgésico no narcótico. La empresa también actively conducting investigación on psoriasis and atopic dermatitis, and has recently been seleccionada for the 2023 K-Bio Health Regional Center Support Program anunció by Incheon Technopark, receiving apoyo for prototype desarrollo, patents and certificacións, and ensayo clínicos. Additionally, la empresa ha sido seleccionada para KOTRA's foreign atracción de inversiones apoyo programa and planea actively pursue overseas atracción de inversiones activities.

Onhil Co., Ltd. is a animal de compañía healthcare plataforma company based on medicina veterinaria under the vision of "One health. One happiness." La empresa is already supplying "DuraHeart SR-3," the world's first 3-month long-acting heartworm vaccine developed with a nacional patent, to animal hospitals. En el futuro, la empresa planea continuar bringing good medicina veterinaria-based products to mercado and grow into a company that contributes more to animal de compañía health.

Through the MOU among three empresas with strong tecnología and sales capabilities, it is esperado that specialized veterinario desarrollo de fármacos in the expanding animal de compañía pharmaceutical mercado will contribute to a healthy and happy coexistence between animal de compañías and humans.